Dr. Navneet Majhail is the Director of the Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial. He also serves as Deputy Physician-in-Chief of Blood Cancers at Sarah Cannon. He specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation and quality of life and late effects in transplant survivors, and he has received funding from the National Cancer Institute and the Patient-Centered Outcomes Research Institute.

Minoo Battiwalla, M.D., M.S. joined Sarah Cannon in 2018 as the director of outcomes research. In his role, he designs and leads retrospective outcomes research across the Sarah Cannon Blood Cancer Network with a special emphasis on blood and marrow stem cell transplantation and cellular therapy. Dr. Battiwalla is actively certified by the American Board of Internal Medicine with further certification in Hematology.

Dr. Wesam Ahmed is a board-certified, fellowship-trained medical oncologist and hematologist at TriStar Bone Marrow Transplant in Nashville, Tennessee. He brings a wealth of experience in operations, clinical research and program development to his work with the Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center.

Dr. Jeremy Pantin received his medical degree from the University of the West Indies, Trinidad and Tobago. He completed his internal medicine residency at Howard University Hospital in Washington, DC, and fellowships in Hematology, Medical Oncology, and Blood and Marrow Transplantation at the National Heart Lung and Blood Institute (NHLBI) at the National Institutes of Health in Bethesda, MD. At completion of his training, Dr. Pantin continued as Staff Clinician at the NHLBI before moving to Augusta University at the Medical College of Georgia (MCG) in Augusta, GA. At MCG, Dr. Pantin introduced haploidentical and cord blood allogeneic transplantation, and started the program for allogeneic transplantation for sickle cell disease.